Inovio Pharmaceuticals, Inc.
$1.24
$0.03 (+2.48%)
$1.21Day Range$1.27
Key Statistics
Market Cap
$128.21M
Shares Outstanding
103.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Dec 8, 1998
Round Lot
100
Locale
US
Trading Data
Day Open
$1.22
Day High
$1.27
Day Low
$1.21
Volume
2.91M
VWAP
$1.24
Prev Close
$1.21
Transactions
--
Acc. Volume
--
About Inovio Pharmaceuticals, Inc.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
PHARMACEUTICAL PREPARATIONSSIC 2834112 employees660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA, 19462(858) 410-3134IPO Dec 8, 1998US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001055726
- Composite FIGI
- BBG000BK6YX5
- Share Class FIGI
- BBG001S5RHZ0
- Ticker Root
- INO
- SIC Code
- 2834
About Inovio Pharmaceuticals, Inc. (INO) Stock
Inovio Pharmaceuticals, Inc. (INO) closed the 2026-09-18 session at $1.24, up 2.48% versus the previous close (+0.03). The stock opened at $1.22 and traded between $1.21 and $1.27 during that session. Session trading volume was 2.9M shares. The volume-weighted average price (VWAP) is $1.24.
Inovio Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer and infectious diseases. INOVIO's platform harnesses the power of in vivo protein production, featuring optimized design and delivery of DNA medicines that teach the body to manufacture its own disease-fighting tools. Its candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease of the respiratory tract caused by HPV infection. In its completed Phase 1/2 clinical trial of INO-3107 for the treatment of HPV-6 and HPV-11-associated RRP.
Inovio Pharmaceuticals, Inc. has a market capitalization of $128.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. INO is listed on the XNAS exchange. The company employs approximately 112 people. Inovio Pharmaceuticals, Inc. is headquartered in PLYMOUTH MEETING, PA. The recorded listing date is 1998-12-08.
On this page you can find market INO stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.